Answers are grounded in this paper and cite their sources.
Evaluates biomarker classifications for Lewy body disease, indicating diagnostic accuracy against autopsy findings.
To evaluate biomarker-based classifications for Lewy body disease (LBD) including synuclein pathology (S), nigral degeneration (N), and genetic risk against autopsy-confirmed pathology in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND).
No takes yet. Share an insight, caveat, or question.
Choudhury et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: